Drug Target Review2026-08-07T14:07:00
Researchers at University of Utah Health have used artificial intelligence and human genetic data to identify a promising early-stage drug candidate targeting WNK2, a protein linked to inherited osteoarthritis, with the lead compound reducing inflammatory gene activity and supporting cartilage cell health in laboratory models.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-11-18T07:00:00Z
Contributor Dr Bryan McClellan and Dr William Matsui, Drug Target Review
2026-11-16T07:00:00Z
Author Dr Martin Baraibar
2023-06-13T13:30:40
Sponsored by NanoTemper Technologies
2026-09-18T15:56:00
Contributor Dr Garegin Papoian, Drug Target Review
2026-09-23T15:00:00
Sponsored by BioIVT
2025-05-08T10:38:52
Sponsored by Takara Bio USA
2026-10-07T14:00:00
Sponsored by WuXi AppTec
2026-09-17T07:00:00
Contributor Dr Roland Bürli, Dr Francesca Capotosti and Dr Antonella Pirone, Drug Target Review
Site powered by Webvision Cloud